Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22118IDB-ST

Select Item

Crohns Disease Pipeline Drugs Market Report Overview

Crohn’s Disease (Regional Enteritis) pipeline market research report provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects.

Key Targets in the Regional Enteritis Pipeline Market

The key targets in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha, Tumor Necrosis Factor, Interleukin 12 Subunit Beta, Integrin Alpha 4, Tyrosine Protein Kinase JAK1, Cannabinoid Receptor 1, and Cannabinoid Receptor 2. Interleukin 23 Subunit Alpha has the highest number of pipeline products.

Regional Enteritis Pipeline Market, by Targets

Regional Enteritis Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Regional Enteritis Pipeline Market

The key MoA in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha Inhibitor, Tumor Necrosis Factor Inhibitor, Interleukin 12 Subunit Beta Inhibitor, Integrin Alpha 4 Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Cannabinoid Receptor 1 Agonist. Interleukin 23 Subunit Alpha Inhibitor has the highest number of pipeline products.

Regional Enteritis Pipeline Market, by MoA

Regional Enteritis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Regional Enteritis Pipeline Market

The key RoA in the regional enteritis pipeline market are oral, subcutaneous, intravenous, topical, rectal, nasal, and parenteral. Oral has the highest number of pipeline products.

Regional Enteritis Pipeline Market, by RoA

Regional Enteritis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Regional Enteritis Pipeline Market

The key molecule types in the regional enteritis pipeline market are small molecule, monoclonal antibody, biologic, cell therapy, recombinant protein, polysaccharide, and gene-modified cell therapy. Small molecule has the highest number of pipeline products.

Regional Enteritis Pipeline Market, by Molecule Types

Regional Enteritis Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Regional Enteritis Pipeline Market

The key companies in the regional enteritis pipeline market are AbbVie Inc, Johnson & Johnson, Dadang & BIO Co Ltd, Boehringer Ingelheim International GmbH, Landos Biopharma Inc, Takeda Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co. AbbVie Inc has the highest number of pipeline products.

Regional Enteritis Pipeline Market, by Companies

Regional Enteritis Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Interleukin 23 Subunit Alpha, Tumor Necrosis Factor, Interleukin 12 Subunit Beta, Integrin Alpha 4, Tyrosine Protein Kinase JAK1, Cannabinoid Receptor 1, and Cannabinoid Receptor 2
Key MoA Interleukin 23 Subunit Alpha Inhibitor, Tumor Necrosis Factor Inhibitor, Interleukin 12 Subunit Beta Inhibitor, Integrin Alpha 4 Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Cannabinoid Receptor 1 Agonist
Key RoA Oral, Subcutaneous, Intravenous, Topical, Rectal, Nasal, and Parenteral
Key molecule types Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Polysaccharide, and Gene-Modified Cell Therapy
Key companies AbbVie Inc, Johnson & Johnson, Dadang & BIO Co Ltd, Boehringer Ingelheim International GmbH, Landos Biopharma Inc, Takeda Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn’s Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn’s Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Gastrointestinal)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Gastrointestinal).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

4D Pharma Plc
9 Meters Biopharma Inc
AbbVie Inc
Abivax SA
Aclaris Therapeutics Inc
Active Biotech AB
Affilogic SAS
AgomAb Therapeutics NV
AIBIOS Co Ltd
Alfasigma SpA
Algernon Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Alvotech ehf
Amide Technologies Inc
Amytrx Therapeutics Inc
Anterogen Co Ltd
Artelo Biosciences Inc
Artizan Biosciences Inc
Asdera LLC
Asieris Pharmaceuticals Co Ltd
Assembly Biosciences Inc
AstraZeneca Plc
Atlantic Healthcare Plc
Avalo Therapeutics Inc
Avesthagen Ltd
Avexegen Therapeutics Inc
Avobis Bio LLC
Avotres Inc
Bio-Thera Solutions Ltd
Biocon Ltd
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cellivery Therapeutics Inc
CELLnLIFE Inc
Celltrion Inc
Cellvation Inc
Celularity Inc
ChemoCentryx Inc
Chong Kun Dang Pharmaceutical Corp
ChunLab Inc
Cloud Pharmaceuticals Inc
Curacle Co Ltd
CVasThera
Cytodyn Inc
Dadang & BIO Co Ltd
Daiichi Sankyo Co Ltd
Defensin Therapeutics ApS
Deka Biosciences Inc
Denali Therapeutics Inc
Direct Biologics LLC
DM Bio Ltd
DNX Biopharmaceuticals Inc
EA Pharma Co Ltd
Eden Biologics Inc
Educell doo
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Enzo Biochem Inc
Exeliom Biosciences SAS
Ferring International Center SA
Finch Therapeutics Group Inc
First Wave BioPharma Inc
FYB 202 GmbH & Co KG
Galactica Biotech Ltd
Galapagos NV
Genentech USA Inc
Genor BioPharma Co Ltd
Giiant Pharma Inc
GlaxoSmithKline Plc
Gossamer Bio Inc
Gusto Global LLC
HAV Vaccines Ltd
Himuka AM Pharma Corp
Hoth Therapeutics Inc
Huaxia Source Cell Engineering Group Co Ltd
Iltoo Pharma
Immix BioPharma Inc
Immunic Inc
Immupharma Plc
InflammatoRx inc
Innovation Pharmaceuticals Inc
Innovative Pharmacology Research
Innovimmune Biotherapeutics Inc
Intract Pharma Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jyant Technologies Inc
Kangstem Biotech Co Ltd
Koutif Therapeutics LLC
Kyorin Pharmaceutical Co Ltd
Landos Biopharma Inc
Lumen Bioscience Inc
Machavert Pharmaceuticals LLC
MAKScientific LLC
Mesoblast Ltd
Metacrine Inc
Metagen Therapeutics Inc
MetiMedi Pharmaceuticals Co Ltd
MGC Pharmaceuticals Ltd
Mitsubishi Tanabe Pharma Corp
Morphic Therapeutic Inc
MRM Health NV
Mycenax Biotech Inc
NeuClone Pty Ltd
Novellus Therapeutics Ltd
Oncodesign SA
Orbsen Therapeutics Ltd
Orchard Therapeutics Plc
PanTheryx Inc
Par'Immune SAS
Paradigm Biopharmaceuticals Ltd
Parvus Therapeutics Inc
PeLeMed Co Ltd
Pfizer Inc
Pharmapraxis
Polpharma Biologics SA
Praeventix LLC
Prestige BioPharma Ltd
Prometheus Biosciences Inc
Puretech Health Plc
Qu Biologics Inc
Rebiotix Inc
Rebus Holdings Inc
RedHill Biopharma Ltd
Redx Pharma Plc
ReForm Biologics Inc
Regentys Corp
Reistone Biopharma Co Ltd
Reponex Pharmaceuticals AS
Saje Pharma LLC
Samsung Bioepis Co Ltd
Sangamo Therapeutics Inc
Saniona AB
Semorex Technologies Ltd
Servatus Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Siam Bioscience Co Ltd
Soligenix Inc
Statera Biopharma Inc
Steel Therapeutics Inc
Stempeutics Research Pvt Ltd
STERO Biotechs Ltd
Sublimity Therapeutics HoldCo Ltd
Suono Bio Inc
Surrozen Inc
Suzhou Pharmavan Cancer Research Center Co Ltd
Synedgen Inc
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Temisis Therapeutics
Tetherex Pharmaceuticals Corp
The Cell Factory BVBA
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tiziana Life Sciences Plc
TRACT Therapeutics Inc
Trio Medicines Ltd
UCB SA
Ventyx Biosciences Inc
VHsquared Ltd
VITAbolus Inc
Vitro Diagnostics Inc
Whan In Pharm Co Ltd
Winston Pharmaceuticals Inc
XBiotech Inc
Yom Chai
YSOPIA Bioscience SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Crohn’s Disease (Regional Enteritis) – Overview

Crohn’s Disease (Regional Enteritis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Crohn’s Disease (Regional Enteritis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Crohn’s Disease (Regional Enteritis) – Companies Involved in Therapeutics Development

Crohn’s Disease (Regional Enteritis) – Drug Profiles

Crohn’s Disease (Regional Enteritis) – Dormant Projects

Crohn’s Disease (Regional Enteritis) – Discontinued Products

Crohn’s Disease (Regional Enteritis) – Product Development Milestones

Featured News & Press Releases

Apr 19, 2022: People with moderate to severe uncontrolled Crohn’s disease granted early access to new investigational treatment in the UK

Apr 04, 2022: Thetis Pharmaceuticals secures $4.2 million from the Helmsley Charitable Trust to advance its first-in-class Resolvin oral therapy for Crohn’s Disease

Mar 30, 2022: Redx nominates GI-targeted ROCK inhibitor, RXC008, as clinical development candidate

Mar 28, 2022: Tiziana commences Phase Ib trial of Crohn’s disease antibody

Mar 24, 2022: Celltrion Healthcare wins tender to supply Remsimato the Brazilian Federal Government

Feb 28, 2022: AbbVie provides update regarding SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe Crohn’s disease in the U.S.

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease

Feb 20, 2022: Rapid improvement and remission in patients with refractory ulcerative colitis and crohn’s colitis after direct injection of Remestemcel-L by colonoscopy

Feb 18, 2022: The majority of adults with moderately to severely active Crohn’s disease in a phase 2 study achieved clinical remission and corticosteroid-free remission through 48 weeks with TREMFYA (guselkumab)

Feb 15, 2022: Statera Biopharma announces Central Institutional Review Board approval of phase 3 clinical trial for pediatric Crohn’s disease

Feb 04, 2022: Tiziana announces submission of amendment to Investigational New Drug Application to advance oral foralumab, a fully human anti-CD3 monoclonal antibody, in patients with crohn’s disease

Feb 04, 2022: Mitsubishi Tanabe’s 9 month sales rise fueled by strong growth in Stelara

Jan 06, 2022: Avalo reports positive phase 1b results for AVTX-002 in moderate to severe Crohn’s disease patients and Presents Additional Program Updates at 2022 Investor Event

Dec 29, 2021: Statera Biopharma submits phase 3 clinical trial protocol to FDA for investigational treatment of pediatric Crohn’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Crohn’s Disease (Regional Enteritis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Crohn’s Disease (Regional Enteritis) – Dormant Projects, 2022

Crohn’s Disease (Regional Enteritis) – Discontinued Products, 2022

Crohn’s Disease (Regional Enteritis) – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Crohn’s Disease (Regional Enteritis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Gastrointestinal reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more